1[1]Ruddy MC. Angiotensin Ⅱ receptor blockade in diabetic nephropathy. (editorial). Am J Hypertens, 2002,15: 468-471.
2[2]Americal Diabetes Association. Diabetic nephropathy. Diabetes Care, 2003,25(Suppl 1) :S94-S98.
3[3]United Kingdom Prospective Diabetes Study. A multicenter study. Ⅲ. Prevalence of hypertension and hypotension therapy in patients with newly diagnosed diabetes. Hypertension,1985,7(Suppl 2): Ⅱ8- Ⅱ 13.
4[4]Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med, 1993,329:1456-1462.
5[5]Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type Ⅱ diabetic patients. Ann Intern Med, 1993,118: 577-581.
6[6]Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE Substudy. Lancet,2000,355: 253-259.
7[7]Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001,45: 851-860.
8[8]Brenner BM, Cooper ME, De Zeeuw D, et al. For the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 2001,345: 861-869.
9[9]Parving HH, Lehnert H, Brochner-Mortensen J, et al. For the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2diabetes. N Engl J Med, 2001,345: 870-878.
10[10]Viberti G,Wheeldon NM. For the MARVAL Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: blood pressure independent effect. Circulation, 2002,106: 672-678.
2Nielsen S,Dollerup J. Losartan reduces albuminuria pa-tients with essential hypenelision. An enalapril controlled 3 months study [J]. Nephrol Dial Transplant,1997,12(2):19-23.
3Makino H,Nakamura Y,Wada J. Remission and regres sion of diabetic nephropathy[J]. Hypertens Res, 2003,26 : 515-519.
4Urata H, Bohem K D, Philip A, et al. Cellular localizationand regional distribution of angiotonsin Ⅱ forming chy-mase in the heart [J]. J Clin Invest, 1993,91:1 269-1 273.
5Mogensen C E, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin systemin patients with hypertension, microalbuminuria ,and non-in-sulin dependent diabetes: the eandesartan and lisinopril microalbuminuria (CALM)study[J]. Br Med J ,2000,321 : 1 440-1 444.
